Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treatment of type C chronic active hepatitis with interferon-alpha 2a. Treatment duration does not influence

A F Attili1, L Natali, L Onori

  • 1Department of Internal Medicine, University of L'Aquila, Italy.

Journal of Clinical Gastroenterology
|October 1, 1994
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modulation of A1 and A2B adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy.

Cell death & disease·2014
Same author

Nuclear DNA changes within Helianthus annuus L.: cytophotometric, karyological and biochemical analyses.

TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik·2013
Same author

Nuclear DNA changes within Helianthus annuus L.: origin and control mechanism.

TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik·2013
Same author

DNA variations in regenerated plants of pea (Pisum sativum L.).

TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik·2013
Same author

Nuclear DNA changes within Helianthus annum L.: changes within single progenies and their relationships with plant development.

TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik·2013
Same author

Heterochromatin and repetitive DNA frequency variation in regenerated plants of Helianthus annuus L.

TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik·2013

Recombinant interferon (IFN)-alpha 2a treatment duration does not impact remission rates for chronic hepatitis C. Longer treatment (6 months) significantly reduces post-treatment relapse compared to shorter durations (3 months).

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Limited data exist on interferon (IFN) treatment duration's effect on biochemical remission and relapse in chronic hepatitis C.
  • Chronic active hepatitis (CAH) requires effective treatment strategies to improve patient outcomes.

Purpose of the Study:

  • To investigate the influence of recombinant IFN-alpha 2a treatment duration on remission and relapse rates in type C CAH patients.
  • To determine optimal treatment duration for maximizing therapeutic benefits and minimizing relapse.

Main Methods:

  • Sixty-two CAH patients were randomized into two groups.
  • Group A received 3 MU of i.m. recombinant IFN-alpha 2a for 3 months.
  • Group B received the same dosage for 6 months.

Related Experiment Videos

Main Results:

  • Biochemical remission rates were similar between the 3-month (62.5%) and 6-month (63.3%) treatment groups (p = NS).
  • Biochemical relapse occurred in 1 patient in group A and 2 patients in group B during treatment.
  • Among responders, relapse rates were significantly lower in the 6-month group (52.9%) compared to the 3-month group (84.2%) (p = 0.04).

Conclusions:

  • IFN treatment duration does not affect the initial biochemical remission rate in type C CAH.
  • Extended IFN treatment duration (6 months) significantly lowers the post-treatment relapse rate.
  • Discontinue IFN treatment after 3 months for non-responders; continue for at least 6 months for responders.